Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
UBS
Medtronic
Moodys
Accenture
Colorcon
Daiichi Sankyo
Cerilliant
Farmers Insurance

Generated: September 21, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ACETAMINOPHEN

« Back to Dashboard

Clinical Trials for Acetaminophen

Trial ID Title Status Sponsor Phase Summary
NCT00000425 Toward Better Outcomes in Osteoarthritis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 3 This study will determine if there is a difference between commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen (a pain-reliever that does not prevent inflammation) for treating knee pain in osteoarthritis (OA). The two main results we will look at are disease progression according to x-rays and disability over 3.5 years. Study participants with moderate knee OA and knee pain will continue taking their NSAID or stop taking their NSAID and start taking acetaminophen. Every 6 months we will send the participants questionnaires that ask about pain, medication use, and disability. We will take x-rays of the knees at the start of the study and again at the end of the study.
NCT00000425 Toward Better Outcomes in Osteoarthritis Completed Stanford University Phase 3 This study will determine if there is a difference between commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen (a pain-reliever that does not prevent inflammation) for treating knee pain in osteoarthritis (OA). The two main results we will look at are disease progression according to x-rays and disability over 3.5 years. Study participants with moderate knee OA and knee pain will continue taking their NSAID or stop taking their NSAID and start taking acetaminophen. Every 6 months we will send the participants questionnaires that ask about pain, medication use, and disability. We will take x-rays of the knees at the start of the study and again at the end of the study.
NCT00000491 Aspirin-Myocardial Infarction Study (AMIS) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To determine whether the daily administration of 1 gm of aspirin to individuals with a documented myocardial infarction would result in a significant reduction in mortality over a three year period.
NCT00000713 A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 To determine the safety of ampligen at several doses in HIV-infected patients who have not yet developed AIDS or advanced AIDS related complex (ARC). Biologic, antiviral, and immunologic effects will be studied. Evidence indicates that a long period with no symptoms follows infection with HIV. Individuals who are infected with the virus could benefit from therapy with a drug that acts to kill the virus or to stimulate the immune system of the individual or both. The immune system is the means the human body has for fighting infections. Ampligen is a suitable drug for clinical trials against HIV because it has been shown to stimulate the immune system and to inhibit HIV in vitro (test tube) at drug levels that can be achieved without noticeable clinical side effects.
NCT00000731 Evaluation of the Interaction Between Acetaminophen and Zidovudine Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A To determine if zidovudine (AZT) and acetaminophen (APAP) interact when given to the same patient, and if so, the manner of interaction. Patients with AIDS often require therapy with painkillers for the management of mild pain and discomfort associated with their disease, and APAP is often prescribed. AZT is being used to treat AIDS patients. It is important for doctors to understand how AZT and APAP may interact when given to the same patient, because other studies have suggested that the dosage of AZT may have to be adjusted when given with APAP in order to avoid or minimize adverse effects.
NCT00000735 A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 To determine the safety of intravenous infusion of ampligen in symptomatic HIV-infected patients at several dose levels, to determine the maximum dose that can be tolerated, and to measure the effects of ampligen on the HIV virus infection, immune function, and clinical condition. Ampligen is a suitable drug for clinical trials against HIV because it has been shown to stimulate the immune system and to inhibit replication of HIV in vitro at doses that can be achieved without noticeable harmful side effects.
NCT00003346 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy consisting of acetaminophen plus carmustine in treating patients who have stage III or stage IV melanoma.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Acetaminophen

Condition Name

Condition Name for Acetaminophen
Intervention Trials
Pain 103
Pain, Postoperative 45
Postoperative Pain 34
Osteoarthritis 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Acetaminophen
Intervention Trials
Pain, Postoperative 120
Osteoarthritis 61
Leukemia 31
Osteoarthritis, Knee 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Acetaminophen

Trials by Country

Trials by Country for Acetaminophen
Location Trials
Canada 71
United Kingdom 28
Korea, Republic of 12
Brazil 11
Italy 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Acetaminophen
Location Trials
Texas 130
New York 75
California 75
Pennsylvania 61
Ohio 55
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Acetaminophen

Clinical Trial Phase

Clinical Trial Phase for Acetaminophen
Clinical Trial Phase Trials
Phase 4 242
Phase 3 135
Phase 2/Phase 3 15
[disabled in preview] 222
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Acetaminophen
Clinical Trial Phase Trials
Completed 373
Recruiting 128
Not yet recruiting 86
[disabled in preview] 146
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Acetaminophen

Sponsor Name

Sponsor Name for Acetaminophen
Sponsor Trials
M.D. Anderson Cancer Center 47
Mallinckrodt 29
Merck Sharp & Dohme Corp. 13
[disabled in preview] 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Acetaminophen
Sponsor Trials
Other 662
Industry 305
NIH 55
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
McKesson
Healthtrust
Merck
Daiichi Sankyo
Citi
Accenture
Argus Health
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.